@thaynabrasilino's tirzepatide claims, fact-checked

What does this video actually claim?

The TikTok from @thaynabrasilino uses Portuguese hashtags promoting weight loss alongside medication names including tirzepatide (Mounjaro) and semaglutide. The post targets weight loss seekers with hashtags like #emagrecer (lose weight) and #magras (skinny), suggesting these GLP-1 medications can help viewers get thin.

While the video doesn't make explicit medical claims in the caption, the hashtag combination clearly markets these prescription diabetes medications as weight loss solutions. The creator appears to be promoting off-label use without medical context.

Does the science support GLP-1s for weight loss?

Yes, but with important caveats. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found tirzepatide at 15mg weekly led to 22.5% body weight reduction over 72 weeks. That's substantially more than the 14.9% seen with 2.4mg semaglutide in STEP 1 (Wilding et al., NEJM, 2021).

But here's what the hashtags don't tell you: participants in these trials also followed reduced-calorie diets and increased physical activity. The FDA approved tirzepatide (Zepbound) for weight management only in people with BMI ≥30 or ≥27 with weight-related conditions.

These aren't magic skinny pills. They're prescription medications with specific medical criteria for use.

What's misleading about this approach?

The hashtag strategy oversimplifies complex medical treatment. Using #magras (skinny) alongside medication names promotes an unrealistic expectation that these drugs will make you thin rather than addressing obesity as a medical condition.

The SURMOUNT trials showed significant side effects: 81% of participants experienced nausea, 31% had diarrhea, and 29% experienced vomiting. About 7.1% discontinued treatment due to adverse events.

Social media weight loss promotion also ignores contraindications. Tirzepatide isn't recommended for people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

What should you actually know about these medications?

GLP-1 receptor agonists work by slowing gastric emptying and affecting appetite-regulating hormones, not by directly burning fat. They require ongoing use; the STEP 1 withdrawal study showed participants regained two-thirds of lost weight within a year of stopping treatment.

Cost matters too. Zepbound runs about $1,000 monthly without insurance coverage. Many insurance plans require documented diet and exercise attempts before approval.

If you're considering these medications, work with a healthcare provider who can evaluate your medical history, current medications, and realistic treatment goals. Social media hashtags aren't medical consultations.